TD Cowen Boosts MDxHealth Price Target to $7.00 with 40% Increase, Maintains Strong Buy Recommendation.

TD Cowen analyst Dan Brennan raised the price target for MDxHealth (MDXH) from $5.00 to $7.00, a 40% increase, and maintained a "Buy" rating. The company provides molecular diagnostic information for cancer treatment. The average target price from 4 analysts is $7.25, indicating a 79.46% upside from the current price.